Table 1.
Licensed prolonged-release opioid agonist therapy products at 31st December 2018
| Pharmaceutical drug | Delivery system | Duration | Brand name | Company | Countries where licensed (year of approval) |
|---|---|---|---|---|---|
| Buprenorphine | Depot injection | 1 month | Sublocade™ | Indivior, Richmond, VA, USA | USA (2017) |
| Buprenorphine | Depot injection | 1 week and 1 month | Buvidal®/ CAM2038 |
Camurus AB, Lund, Sweden | Europe (2018) and Australia (2018) |
| Buprenorphine | Implant | 6 months | Probuphine® | Titan Pharmaceuticals, Inc., San Francisco, CA, USA | USA (2016) |